pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Auvelity
drug
save

(bupropion hydrochloride + dextromethorphan) ER

Marketedupdated 2mo ago
by $AXSM Axsome Therapeutics, Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • drugAUVELITY7 co-mentions · 4 sources
  • tagApproval6 co-mentions · 3 sources
  • drugbupropion hydrochloride ER4 co-mentions · 4 sources
  • drugWELLBUTRIN SR4 co-mentions · 4 sources
  • drugWELLBUTRIN4 co-mentions · 4 sources
  • drugbupropion4 co-mentions · 4 sources
  • drugBUPROPION HYDROCHLORIDE4 co-mentions · 4 sources
  • drugbupropion hydrochloride MR4 co-mentions · 4 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 7 investigational indications.

indications

investigational
Major Depression

all catalysts(4)

approval · 3
Aug 18, 2022
approval
$AXSM238.66+0.72%
4y ago
AUVELITY (BUPROPION HYDROCHLORIDE) — FDA approval
(bupropion hydrochloride + dextromethorphan) ER
→
May 7, 2024
approval
$AXSM238.66+0.72%
2y ago
AUVELITY (BUPROPION HYDROCHLORIDE) — FDA approval
(bupropion hydrochloride + dextromethorphan) ER
→
Nov 5, 2025
approval
$AXSM238.66+0.72%
9mo ago
AUVELITY (BUPROPION HYDROCHLORIDE) — FDA approval
(bupropion hydrochloride + dextromethorphan) ER
→
pdufa · 1
Apr 30, 2026
pdufa
$AXSM238.66+0.72%
3mo ago
Axsome Therapeutics Inc — (bupropion hydrochloride + dextromethorphan) ER (PDUFA)
(bupropion hydrochloride + dextromethorphan) ER
→

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 29, 2033
~7.3 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (130)

  • Apr 20, 2043method-of-use (U-3778)US 11844797
  • Mar 2, 2043method-of-use (U-3419)US 11839612
  • Feb 23, 2043method-of-use (U-3419)US 11752144
  • Feb 23, 2043method-of-use (U-3419)US 12042473
  • Feb 23, 2043method-of-use (U-3419)US 12146889
  • Feb 15, 2043method-of-use (U-3419)US 11986444
  • Feb 15, 2043method-of-use (U-3419)US 12036191
  • Jan 23, 2043method-of-use (U-3419)US 11730706
  • Jan 23, 2043method-of-use (U-3419)US 11883373
  • Jan 20, 2043method-of-use (U-3419)US 11717518
  • Jan 20, 2043method-of-use (U-3419)US 11925636
  • Jan 20, 2043formulationUS 12156914
  • Jan 20, 2043method-of-use (U-3419)US 12310961
  • Jan 20, 2043method-of-use (U-3419)US 12357697
  • Dec 1, 2041method-of-use (U-3419)US 11896563
  • Dec 1, 2041method-of-use (U-3419)US 12390428
  • Jan 7, 2040method-of-use (U-3419)US 10780064
  • Jan 7, 2040method-of-use (U-3419)US 10925842
  • Jan 7, 2040method-of-use (U-3419)US 10940124
  • Jan 7, 2040method-of-use (U-3419)US 10966942
  • Nov 9, 2034method-of-use (U-3419)US 10780066
  • Nov 5, 2034method-of-use (U-3419)US 10058518
  • Nov 5, 2034method-of-use (U-3419)US 10064857
  • Nov 5, 2034method-of-use (U-3419)US 10080727
  • Nov 5, 2034method-of-use (U-3419)US 10092560
  • Nov 5, 2034method-of-use (U-3419)US 10092561
  • Nov 5, 2034method-of-use (U-3419)US 10105327
  • Nov 5, 2034method-of-use (U-3419)US 10105361
  • Nov 5, 2034method-of-use (U-3419)US 10251879
  • Nov 5, 2034method-of-use (U-3419)US 10463634
  • Nov 5, 2034method-of-use (U-3419)US 10512643
  • Nov 5, 2034method-of-use (U-3419)US 10548857
  • Nov 5, 2034method-of-use (U-3419)US 10596167
  • Nov 5, 2034method-of-use (U-3419)US 10772850
  • Nov 5, 2034method-of-use (U-3419)US 10786469
  • Nov 5, 2034method-of-use (U-3419)US 10786496
  • Nov 5, 2034method-of-use (U-3419)US 10799497
  • Nov 5, 2034method-of-use (U-3419)US 10806710
  • Nov 5, 2034method-of-use (U-3419)US 10864209
  • Nov 5, 2034method-of-use (U-3419)US 10874663
  • Nov 5, 2034method-of-use (U-3419)US 10874664
  • Nov 5, 2034method-of-use (U-3419)US 10874665
  • Nov 5, 2034method-of-use (U-3419)US 10881624
  • Nov 5, 2034method-of-use (U-3419)US 10881657
  • Nov 5, 2034method-of-use (U-3419)US 10894046
  • Nov 5, 2034method-of-use (U-3419)US 10894047
  • Nov 5, 2034method-of-use (U-3419)US 10898453
  • Nov 5, 2034method-of-use (U-3419)US 10933034
  • Nov 5, 2034method-of-use (U-3419)US 10945973
  • Nov 5, 2034method-of-use (U-3419)US 10966941
  • Nov 5, 2034method-of-use (U-3419)US 10966974
  • Nov 5, 2034method-of-use (U-3419)US 11020389
  • Nov 5, 2034method-of-use (U-3419)US 11058648
  • Nov 5, 2034method-of-use (U-3419)US 11065248
  • Nov 5, 2034method-of-use (U-3419)US 11090300
  • Nov 5, 2034method-of-use (U-3419)US 11096937
  • Nov 5, 2034method-of-use (U-3419)US 11123343
  • Nov 5, 2034method-of-use (U-3419)US 11123344
  • Nov 5, 2034method-of-use (U-3419)US 11129826
  • Nov 5, 2034method-of-use (U-3419)US 11141388
  • Nov 5, 2034method-of-use (U-3419)US 11141416
  • Nov 5, 2034method-of-use (U-3419)US 11147808
  • Nov 5, 2034method-of-use (U-3419)US 11185515
  • Nov 5, 2034formulationUS 11191739
  • Nov 5, 2034formulationUS 11197839
  • Nov 5, 2034method-of-use (U-3419)US 11207281
  • Nov 5, 2034method-of-use (U-3419)US 11213521
  • Nov 5, 2034method-of-use (U-3419)US 11229640
  • Nov 5, 2034method-of-use (U-3419)US 11234946
  • Nov 5, 2034method-of-use (U-3419)US 11253491
  • Nov 5, 2034method-of-use (U-3419)US 11253492
  • Nov 5, 2034method-of-use (U-3419)US 11273133
  • Nov 5, 2034method-of-use (U-3419)US 11273134
  • Nov 5, 2034method-of-use (U-3419)US 11285118
  • Nov 5, 2034method-of-use (U-3419)US 11285146
  • Nov 5, 2034method-of-use (U-3419)US 11291638
  • Nov 5, 2034method-of-use (U-3419)US 11291665
  • Nov 5, 2034method-of-use (U-3419)US 11298351
  • Nov 5, 2034method-of-use (U-3419)US 11298352
  • Nov 5, 2034method-of-use (U-3419)US 11311534
  • Nov 5, 2034method-of-use (U-3419)US 11344544
  • Nov 5, 2034method-of-use (U-3419)US 11357744
  • Nov 5, 2034method-of-use (U-3419)US 11364233
  • Nov 5, 2034method-of-use (U-3419)US 11382874
  • Nov 5, 2034method-of-use (U-3419)US 11419867
  • Nov 5, 2034method-of-use (U-3419)US 11426370
  • Nov 5, 2034method-of-use (U-3419)US 11426401
  • Nov 5, 2034formulationUS 11433067
  • Nov 5, 2034method-of-use (U-3419)US 11439636
  • Nov 5, 2034method-of-use (U-3419)US 11478468
  • Nov 5, 2034method-of-use (U-3419)US 11497721
  • Nov 5, 2034method-of-use (U-3419)US 11510918
  • Nov 5, 2034method-of-use (U-3419)US 11517542
  • Nov 5, 2034method-of-use (U-3419)US 11517543
  • Nov 5, 2034method-of-use (U-3419)US 11524007
  • Nov 5, 2034method-of-use (U-3419)US 11524008
  • Nov 5, 2034formulationUS 11534414
  • Nov 5, 2034method-of-use (U-3419)US 11541021
  • Nov 5, 2034method-of-use (U-3419)US 11541048
  • Nov 5, 2034method-of-use (U-3419)US 11571417
  • Nov 5, 2034method-of-use (U-3419)US 11576909
  • Nov 5, 2034method-of-use (U-3419)US 11590124
  • Nov 5, 2034method-of-use (U-3419)US 11596627
  • Nov 5, 2034method-of-use (U-3419)US 11617728
  • Nov 5, 2034method-of-use (U-3563)US 11617747
  • Nov 5, 2034method-of-use (U-3419)US 11779579
  • Nov 5, 2034method-of-use (U-3419)US 11969421
  • Nov 5, 2034method-of-use (U-3419)US 12109178
  • Nov 5, 2034method-of-use (U-3419)US 9168234
  • Nov 5, 2034method-of-use (U-3419)US 9198905
  • Nov 5, 2034method-of-use (U-3419)US 9205083
  • Nov 5, 2034method-of-use (U-3419)US 9238032
  • Nov 5, 2034method-of-use (U-3419)US 9278095
  • Nov 5, 2034method-of-use (U-3419)US 9314462
  • Nov 5, 2034method-of-use (U-3419)US 9370513
  • Nov 5, 2034method-of-use (U-3419)US 9375429
  • Nov 5, 2034method-of-use (U-3419)US 9408815
  • Nov 5, 2034method-of-use (U-3419)US 9421176
  • Nov 5, 2034method-of-use (U-3419)US 9457023
  • Nov 5, 2034method-of-use (U-3419)US 9457025
  • Nov 5, 2034method-of-use (U-3419)US 9474731
  • Nov 5, 2034method-of-use (U-3419)US 9486450
  • Nov 5, 2034method-of-use (U-3419)US 9700528
  • Nov 5, 2034method-of-use (U-3419)US 9700553
  • Nov 5, 2034method-of-use (U-3419)US 9707191
  • Nov 5, 2034method-of-use (U-3419)US 9763932
  • Nov 5, 2034method-of-use (U-3419)US 9861595
  • Nov 5, 2034method-of-use (U-3419)US 9867819
  • Nov 5, 2034method-of-use (U-3419)US 9968568
  • Oct 29, 2033formulationUS 8569328

News(0)

no news has mentioned this drug yet

brand
Auvelity
generic
(bupropion hydrochloride + dextromethorphan [INN])
MOA
12.1 Mechanism of Action Dextromethorphan is an uncompetitive antagonist of the NMDA receptor (an ionotropic glutamate receptor) and a sigma-1 receptor agonist. The mechanism of dextromethorphan in the treatment of MDD is unclear. The mechanism of action of bupropion in the treatment of MDD is unclear; however, it may be related to noradrenergic and/or dopaminergic mechanisms. Bupropion increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.
indication
Dementia Associated With Alzheimer's Disease
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?